

## Needle Biopsy Associated Tumor Tracking of Adenocarcinoma of the Prostate

Sheldon S. Bastacky, Patrick C. Walsh, and Jonathan I. Epstein:

**Journal of Urology; 145:1003-1007, May 1991.**

Our data suggest that subclinical seeding is a more prevalent process than was formerly believed. In particular, tumor seeding within the needle track can occur following transrectal biopsy, a phenomenon that has never been previously recognized. Furthermore, our study also demonstrates the novel finding of seeding following the thinneedle biopsy gun technique." (3 of 7 patients).

In view of these findings, it is important for physicians to realize that they may no longer be dealing with stages A or B. It is essential to watch for this phenomenon, and if present, the patient's disease should be upstaged to pathological stage C and dealt with accordingly. This information seems not to be common knowledge among many physicians.

According to Dr. Ronald Wheeler, a Sarasota Florida based Urologist, "**Needle Tracking takes place with every prostate biopsy.**" "Based upon acceptance of a 'decades old' inferior protocol for prostate tissue sampling in concert with a concordant lack of precision imaging to guide biopsies accurately, every time cancer is found, cancer cells are spread."

"The low predictive value for the prostate biopsy procedure is directly correlated with a marker (PSA) that is more readily recognized as a marker for inflammation than prostate cancer. To no one's surprise, therefore, this is the reason PSA lacks specificity in prostate cancer detection and the reason 3.0 Tesla MRI-Spectroscopy has become the designated imaging exam of excellence at the Diagnostic Center for Disease."